Key statistics
As of last trade, Eupraxia Pharmaceuticals Inc (EPRX:TOR) traded at 4.71, 53.42% above the 52 week low of 3.07 set on Oct 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.72 |
---|---|
High | 4.72 |
Low | 4.70 |
Bid | 4.70 |
Offer | 4.73 |
Previous close | 4.73 |
Average volume | 41.87k |
---|---|
Shares outstanding | 35.62m |
Free float | 30.47m |
P/E (TTM) | -- |
Market cap | 168.49m CAD |
EPS (TTM) | -1.38 CAD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:42 GMT.
More ▼
- Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
- Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
- Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
- Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
- Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
- Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
- Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
- Eupraxia Pharmaceuticals Strengthens Senior Management Team
More ▼